Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
20/20 Biolabs Inc. (AIDX) had Cost of Goods Sold of 1.44M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
2.05M |
|
-3.74M |
|
|
Cost of Goods Sold |
1.44M |
0.60M |
|
5.38M |
|
-3.33M |
|
-0.41M |
|
-3.74M |
|
-3.74M |
|
-3.74M |
|
-3.74M |
|
-3.74M |
|
-3.74M |
|
-3.33M |
|
-3.14M |
|
4.93M |
|
4.93M |
|
-0.76 |
|
-0.76 |
|
| Balance Sheet Financials | |
1.47M |
|
0.06M |
|
2.67M |
|
4.14M |
|
2.46M |
|
0.62M |
|
1.69M |
|
4.16M |
|
-0.07M |
|
-1.10M |
|
-0.02M |
|
5.44M |
|
| Cash Flow Statement Financials | |
-1.92M |
|
-- |
|
1.16M |
|
1.78M |
|
1.03M |
|
-0.76M |
|
0.52M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.60 |
|
-- |
|
-- |
|
1.03 |
|
-36.10 |
|
29.56% |
|
-162.87% |
|
-162.87% |
|
-153.42% |
|
-182.82% |
|
-182.82% |
|
-1.92M |
|
-- |
|
-- |
|
-- |
|
0.49 |
|
12.40 |
|
10.23 |
|
35.69 |
|
5630.55% |
|
340.54% |
|
-90.37% |
|
-623.00% |
|
-0.00 |
|
-0.39 |
|
-0.39 |
|